Skip to main content
SpringerLink
Log in

Pathogenesis and Management of Venous Thromboembolism in Cancer Patients

  • Chapter
  • First Online:
Supportive Care in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 712 Accesses

Abstract

One hundred and forty one years have passed since Armand Trousseau’s initial observation that venous thromboembolism (VTE) is a common manifestation of an underlying malignancy (1). Despite widespread recognition of this association and the availability of a multiple options for prevention and treatment of venous thrombosis, VTE remains a common cause of morbidity and mortality in cancer patients. The purpose of this chapter will be to review: (1) The epidemiology of VTE in cancer patients, (2) The pathogenesis of cancer-related thrombosis, (3) The prevention and treatment of VTE in the cancer patient, and (4) Special topics in VTE management including management of recurrent VTE and heparin-induced thrombocytopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Trousseau A. Phlegmasia alba dolens. In: Trouuseau A, editor. Clinique Medicale de l’Hotel-Dieu de Paris. Paris: Balliere, 1865: 654–712.

    Google Scholar 

  2. Heit JA, Silverstein MD, Mohr DN. et al. 2000; Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 160:(6)809–815.

    PubMed  CAS  Google Scholar 

  3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. 2005; Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 293:(6)715–722.

    PubMed  CAS  Google Scholar 

  4. Deitcher SR. 2003; Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis. 16:(1–2)21–31.

    PubMed  CAS  Google Scholar 

  5. Levitan N, Dowlati A, Remick SC. et al. 1999; Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 78:(5)285–291.

    CAS  Google Scholar 

  6. Blom JW, Vanderschoot JP, Oostindier MJ. et al. 2006; Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 4:(3)529–535.

    PubMed  CAS  Google Scholar 

  7. Stein PD, Beemath A, Meyers FA. et al. 2006; Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 119:(1)60–68.

    PubMed  Google Scholar 

  8. Khorana AA, Francis CW, Culakova E. et al. 2006; Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 24:(3)484–490.

    PubMed  Google Scholar 

  9. Chew HK, Wun T, Harvey D. et al. 2006; Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 166:(4)458–464.

    PubMed  Google Scholar 

  10. Ogren M, Bergqvist D, Wahlander K. et al. 2006; Trousseau’s syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost. 95:(3)541–545.

    PubMed  Google Scholar 

  11. Blom JW, Osanto S, Rosendaal FR. 2004; The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2:(10)1760–1765.

    PubMed  CAS  Google Scholar 

  12. Baron JA, Gridley G, Weiderpass E. et al. 1998; Venous thromboembolism and cancer. Lancet. 351:(9109)1077–1080.

    PubMed  CAS  Google Scholar 

  13. Sorensen HT, Mellemkjaer L, Steffensen FH. et al. 1998; The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 338:(17)1169–1173.

    PubMed  CAS  Google Scholar 

  14. Piccioli A, Lensing AW, Prins MH. et al. 2004; Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2:(6)884–889.

    PubMed  CAS  Google Scholar 

  15. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000; Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 343:(25)1846–1850.

    PubMed  CAS  Google Scholar 

  16. Semeraro N, Colucci M. 1997; Tissue factor in health and disease. Thromb Haemost. 78:(1)759–764.

    PubMed  CAS  Google Scholar 

  17. Rong Y, Post DE, Pieper RO. et al. 2005; PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 65:(4)1406–1413.

    PubMed  CAS  Google Scholar 

  18. Hamada K, Kuratsu J, Saitoh Y. et al. 1996; Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer. 77:(9)1877–1883.

    PubMed  CAS  Google Scholar 

  19. Wojtukiewicz MZ, Rucinska M, Zacharski LR. et al. 2001; Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost. 86:(6)1416–1420.

    PubMed  CAS  Google Scholar 

  20. Gordon SG. 1992; Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost. 18:(4)424–433.

    PubMed  CAS  Google Scholar 

  21. Hettasch JM, Bandarenko N, Burchette JL. et al. 1996; Tissue transglutaminase expression in human breast cancer. Lab Invest. 75:(5)637–645.

    PubMed  CAS  Google Scholar 

  22. Barbui T, Finazzi G, Falanga A. 1998; The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 91:(9)3093–3102.

    PubMed  CAS  Google Scholar 

  23. Kwaan HC, Keer HN, Radosevich JA. et al. 1991; Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost. 17:(3)175–182.

    PubMed  CAS  Google Scholar 

  24. Falanga A, Rickles FR. 1999; Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 25:(2)173–182.

    PubMed  CAS  Google Scholar 

  25. Nash GF, Walsh DC, Kakkar AK. 2001; The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2:(10)608–613.

    PubMed  CAS  Google Scholar 

  26. Streiff MB, Segal J, Grossman SA. et al. 2004; ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 100:(8)1717–1723.

    PubMed  Google Scholar 

  27. Jick H, Porter J. 1978; Thrombophlebitis of the lower extremities and ABO blood type. Arch Intern Med. 138:(10)1566–1567.

    PubMed  CAS  Google Scholar 

  28. Talbot S, Wakley EJ, Ryrie D, Langman MJ. 1970; ABO blood groups and venous thromboembolic disease. Lancet. 1:(7659)1257–1259.

    PubMed  CAS  Google Scholar 

  29. O’Donnell J, Laffan MA. 2001; The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 11:(4)343–351.

    PubMed  Google Scholar 

  30. O’Donnell J, Mumford AD, Manning RA, Laffan M. 2000; Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 83:(1)10–13.

    PubMed  Google Scholar 

  31. Kraaijenhagen RA, in’t Anker PS, Koopman MM. et al. 2000; High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 83:(1)5–9.

    PubMed  CAS  Google Scholar 

  32. Kyrle PA, Minar E, Hirschl M. et al. 2000; High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 343:(7)457–462.

    PubMed  CAS  Google Scholar 

  33. Ramacciotti E, Wolosker N, Puech-Leao P. et al. 2003; Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res. 109:(4)171–174.

    PubMed  CAS  Google Scholar 

  34. Pihusch R, Danzl G, Scholz M. et al. 2002; Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 94:(12)3120–3126.

    PubMed  CAS  Google Scholar 

  35. Abramson N, Costantino JP, Garber JE. et al. 2006; Effect of factor V Leiden and prothrombin G20210 → A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial J Natl Cancer Inst. 98:(13)904–910.

    PubMed  CAS  Google Scholar 

  36. Beer JH, Haeberli A, Vogt A. et al. 2002; Coagulation markers predict survival in cancer patients. Thromb Haemost. 88:(5)745–749.

    PubMed  CAS  Google Scholar 

  37. White RH, Zhou H, Romano PS. 2003; Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 90:(3)446–455.

    PubMed  CAS  Google Scholar 

  38. Jhingran A, Eifel PJ. 2000; Perioperative and postoperative complications of intracavitary radiation for FIGO stage I-III carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 46:(5)1177–1183.

    PubMed  CAS  Google Scholar 

  39. Holm T, Singnomklao T, Rutqvist LE, 1996; Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long-term follow-up of two randomized trials. Cancer. 78:(5)968–976.

    PubMed  CAS  Google Scholar 

  40. Silvani A, Salmaggi A, Eoli M. et al. 2003; Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. Neurol Sci. 24:(4)272.

    PubMed  CAS  Google Scholar 

  41. Weitz IC, Israel VK, Waisman JR. et al. 2002; Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 88:(2)213–220.

    PubMed  CAS  Google Scholar 

  42. Edwards RL, Klaus M, Matthews E. et al. 1990; Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 89:(1)25–28.

    PubMed  CAS  Google Scholar 

  43. Khorana AA, Francis CW, Culakova E, Lyman GH. 2005; Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 104:(12)2822–2829.

    PubMed  Google Scholar 

  44. Levine MN, Gent M, Hirsh J. et al. 1988; The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 318:(7)404–407.

    PubMed  CAS  Google Scholar 

  45. Goodnough LT, Saito H, Manni A. et al. 1984; Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 54:(7)1264–1268.

    PubMed  CAS  Google Scholar 

  46. Saphner T, Tormey DC, Gray R. 1991; Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 9:(2)286–294.

    PubMed  CAS  Google Scholar 

  47. Pritchard KI, Paterson AH, Paul NA. et al. 1996; Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 14:(10)2731–2737.

    PubMed  CAS  Google Scholar 

  48. Bonneterre J, Buzdar A, Nabholtz JM. et al. 2001; Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92:(9)2247–2258.

    PubMed  CAS  Google Scholar 

  49. Weijl NI, Rutten MF, Zwinderman AH. et al. 2000; Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 18:(10)2169–2178.

    PubMed  CAS  Google Scholar 

  50. Numico G, Garrone O, Dongiovanni V. et al. 2005; Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 103:(5)994–999.

    PubMed  Google Scholar 

  51. Jacobson GM, Kamath RS, Smith BJ, Goodheart MJ. 2005; Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 96:(2)470–474.

    PubMed  CAS  Google Scholar 

  52. Priest JR, Ramsay NK, Steinherz PG. et al. 1982; A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 100:(6)984–989.

    PubMed  CAS  Google Scholar 

  53. Alberts SR, Bretscher M, Wiltsie JC. et al. 1999; Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma. 32:(5–6)489–496.

    PubMed  CAS  Google Scholar 

  54. Priest JR, Ramsay NK, Bennett AJ. et al. 1982; The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 100:(6)990–995.

    PubMed  CAS  Google Scholar 

  55. Liebman HA, Wada JK, Patch MJ, McGehee W. 1982; Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 50:(3)451–456.

    PubMed  CAS  Google Scholar 

  56. Otten HM, Mathijssen J, ten Cate H. et al. 2004; Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 164:(2)190–194.

    PubMed  Google Scholar 

  57. Edwards RL, Klaus M, Matthews E. et al. 1990; Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 89:(1)25–28.

    PubMed  CAS  Google Scholar 

  58. Zangari M, Anaissie E, Barlogie B. et al. 2001; Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 98:(5)1614–1615.

    PubMed  CAS  Google Scholar 

  59. Rajkumar SV, Hayman S, Gertz MA. et al. 2002; Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 20:(21)4319–4323.

    PubMed  CAS  Google Scholar 

  60. Zangari M, Siegel E, Barlogie B. et al. 2002; Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 100:(4)1168–1171.

    PubMed  CAS  Google Scholar 

  61. Zangari M, Saghafifar F, Anaissie E. et al. 2002; Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 13:(3)187–192.

    PubMed  CAS  Google Scholar 

  62. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. 2003; Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 1:(3)445–449.

    PubMed  CAS  Google Scholar 

  63. Baz R, Li L, Kottke-Marchant K. et al. 2005; The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 80:(12)1568–1574.

    PubMed  CAS  Google Scholar 

  64. Zangari M, Barlogie B, Anaissie E. et al. 2004; Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 126:(5)715–721.

    PubMed  CAS  Google Scholar 

  65. Ikhlaque N, Seshadri V, Kathula S, Baumann MA. 2006; Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol. 81:(6)420–422.

    PubMed  CAS  Google Scholar 

  66. Knight R, DeLap RJ, Zeldis JB. 2006; Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 354:(19)2079–2080.

    PubMed  CAS  Google Scholar 

  67. Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. 2003; Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 21:(1)60–65.

    PubMed  CAS  Google Scholar 

  68. Shah MA, Ilson D, Kelsen DP. 2005; Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 23:(11)2574–2576.

    PubMed  Google Scholar 

  69. Kuenen BC, Rosen L, Smit EF. et al. 2002; Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 20:(6)1657–1667.

    PubMed  CAS  Google Scholar 

  70. Brotman DJ, Girod JP, Posch A. et al. 2006; Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 118:(2)247–252.

    PubMed  CAS  Google Scholar 

  71. Verso M, Agnelli G. 2003; Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 21:(19)3665–3675.

    PubMed  Google Scholar 

  72. Wun T, Law L, Harvey D. et al. 2003; Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 98:(7)1514–1520.

    PubMed  CAS  Google Scholar 

  73. Steurer M, Sudmeier I, Stauder R, Gastl G. 2003; Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 121:(1)101–103.

    PubMed  CAS  Google Scholar 

  74. Vansteenkiste J, Pirker R, Massuti B. et al. 2002; Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 94:(16)1211–1220.

    PubMed  CAS  Google Scholar 

  75. Galli M, Elice F, Crippa C. et al. 2004; Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica. 89:(9)1141–1142.

    PubMed  CAS  Google Scholar 

  76. Feagan BG, Wong CJ, Kirkley A. et al. 2000; Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 133:(11)845–854.

    PubMed  CAS  Google Scholar 

  77. Smith KJ, Bleyer AJ, Little WC, Sane DC. 2003; The cardiovascular effects of erythropoietin. Cardiovasc Res. 59:(3)538–548.

    PubMed  CAS  Google Scholar 

  78. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924.

    PubMed  CAS  Google Scholar 

  79. Lin A, Ryu J, Harvey D. et al. 2006; Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. Gynecol Oncol. 102:(1)98–102.

    PubMed  CAS  Google Scholar 

  80. Bratzler DW, Raskob GE, Murray CK. et al. 1998; Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 158:(17)1909–1912.

    PubMed  CAS  Google Scholar 

  81. Rahim SA, Panju A, Pai M, Ginsberg J. 2003; Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thromb Res. 111:(4–5)215–219.

    PubMed  CAS  Google Scholar 

  82. Goldhaber SZ, Tapson VF. 2004; A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 93:(2)259–262.

    PubMed  Google Scholar 

  83. Kakkar AK, Levine M, Pinedo HM. et al. 2003; Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 8:(4)381–388.

    PubMed  Google Scholar 

  84. Stein PD, Beemath A, Meyers FA. et al. 2006; Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 119:(1)60–68.

    PubMed  Google Scholar 

  85. Kakkar AK, Williamson RC. 1999; Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost. 25:(2)239–243.

    PubMed  CAS  Google Scholar 

  86. Mismetti P, Laporte S, Darmon JY. et al. 2001; Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 88:(7)913–930.

    PubMed  CAS  Google Scholar 

  87. . Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84(8):1099–1103.

    Google Scholar 

  88. McLeod RS, Geerts WH, Sniderman KW. et al. 2001; Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg. 233:(3)438–444.

    PubMed  CAS  Google Scholar 

  89. Agnelli G, Bergqvist D, Cohen AT. et al. 2005; Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 92:(10)1212–1220.

    PubMed  CAS  Google Scholar 

  90. Agnelli G, Bolis G, Capussotti L. et al. 2006; A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 243:(1)89–95.

    PubMed  Google Scholar 

  91. Bergqvist D, Agnelli G, Cohen AT. et al. 2002; Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 346:(13)975–980.

    PubMed  CAS  Google Scholar 

  92. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. et al. 2006; Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 4:(11)2384–2390.

    PubMed  CAS  Google Scholar 

  93. Roderick P, Ferris G, Wilson K. et al. 2005; Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 9:(49)iii–x, 1.

    PubMed  CAS  Google Scholar 

  94. Geerts WH, Heit JA, Clagett GP. et al. 2001; Prevention of venous thromboembolism. Chest. 119:(1 Suppl)132S–175S.

    PubMed  CAS  Google Scholar 

  95. Comerota AJ, Katz ML, White JV. 1992; Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg. 164:(3)265–268.

    PubMed  CAS  Google Scholar 

  96. Cornwell EE, III, Chang D, Velmahos G. et al. 2002; Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg. 68:(5)470–473.

    PubMed  Google Scholar 

  97. Agnelli G, Piovella F, Buoncristiani P. et al. 1998; Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 339:(2)80–85.

    PubMed  CAS  Google Scholar 

  98. Ramos R, Salem BI, De Pawlikowski MP. et al. 1996; The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest. 109:(1)82–85.

    PubMed  CAS  Google Scholar 

  99. Kroger K, Weiland D, Ose C. et al. 2006; Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 17:(2)297–303.

    PubMed  CAS  Google Scholar 

  100. Mismetti P, Laporte-Simitsidis S, Tardy B. et al. 2000; Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 83:(1)14–19.

    PubMed  CAS  Google Scholar 

  101. Samama MM, Cohen AT, Darmon JY. et al. 1999; A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 341:(11)793–800.

    PubMed  CAS  Google Scholar 

  102. Lechler E, Schramm W, Flosbach CW. 1996; The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 26:(Suppl 2)49–56.

    PubMed  CAS  Google Scholar 

  103. Kleber FX, Witt C, Vogel G. et al. 2003; Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 145:(4)614–621.

    PubMed  CAS  Google Scholar 

  104. Leizorovicz A, Cohen AT, Turpie AG. et al. 2004; Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 110:(7)874–879.

    PubMed  CAS  Google Scholar 

  105. Cohen AT, Davidson BL, Gallus AS. et al. 2006; Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 332:(7537)325–329.

    PubMed  CAS  Google Scholar 

  106. Blom JW, Osanto S, Rosendaal FR. 2006; High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer. 42:(3)410–414.

    PubMed  CAS  Google Scholar 

  107. Monreal M, Raventos A, Lerma R. et al. 1994; Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost. 72:(4)548–550.

    PubMed  CAS  Google Scholar 

  108. Bern MM, Lokich JJ, Wallach SR. et al. 1990; Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 112:(6)423–428.

    PubMed  CAS  Google Scholar 

  109. Monreal M, Alastrue A, Rull M. et al. 1996; Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 75:(2)251–253.

    PubMed  CAS  Google Scholar 

  110. Karthaus M, Kretzschmar A, Kroning H. et al. 2006; Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 17:(2)289–296.

    PubMed  CAS  Google Scholar 

  111. Verso M, Agnelli G, Bertoglio S. et al. 2005; Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 23:(18)4057–4062.

    PubMed  CAS  Google Scholar 

  112. Wells PS. 2005; The role of qualitative D-dimer assays, clinical probability, and noninvasive imaging tests for the diagnosis of deep vein thrombosis and pulmonary embolism. Semin Vasc Med. 5:(4)340–350.

    PubMed  Google Scholar 

  113. Oudega R, Hoes AW, Moons KG. 2005; The Wells rule does not adequately rule out deep venous thrombosis in primary care patients. Ann Intern Med. 143:(2)100–107.

    PubMed  Google Scholar 

  114. Lee AY, Julian JA, Levine MN. et al. 1999; Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 131:(6)417–423.

    PubMed  CAS  Google Scholar 

  115. Sohne M, Kruip MJ, Nijkeuter M. et al. 2006; Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost. 4:(5)1042–1046.

    PubMed  CAS  Google Scholar 

  116. Buller HR, Agnelli G, Hull RD. et al. 2004; Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)401S–428S.

    PubMed  CAS  Google Scholar 

  117. Segal JB, Bolger DT, Jenckes MW. et al. 2003; Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med. 115:(4)298–308.

    PubMed  CAS  Google Scholar 

  118. Warkentin TE, Greinacher A. 2004; Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)311S–337S.

    PubMed  CAS  Google Scholar 

  119. Kearon C, Ginsberg JS, Julian JA. et al. 2006; Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 296:(8)935–942.

    PubMed  CAS  Google Scholar 

  120. Martel N, Lee J, Wells PS. 2005; Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 106:(8)2710–2715.

    PubMed  CAS  Google Scholar 

  121. Kuo KH, Kovacs MJ. 2005; Fondaparinux: a potential new therapy for HIT. Hematology. 10:(4)271–275.

    PubMed  CAS  Google Scholar 

  122. Warkentin TE, Maurer BT, Aster RH. Heparin-Induced Thrombocytopenia Associated with Fondaparinux. New Eng J Med. 2007;356(25):2653–2655.

    PubMed  CAS  Google Scholar 

  123. Merli G, Spiro TE, Olsson CG. et al. 2001; Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:(3)191–202.

    PubMed  CAS  Google Scholar 

  124. Crowther MA, Berry LR, Monagle PT, Chan AK. 2002; Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 116:(1)178–186.

    PubMed  CAS  Google Scholar 

  125. Bijsterveld NR, Moons AH, Boekholdt SM. et al. 2002; Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 106:(20)2550–2554.

    PubMed  CAS  Google Scholar 

  126. Ageno W, Grimwood R, Limbiati S. et al. 2005; Home-treatment of deep vein thrombosis in patients with cancer. Haematologica. 90:(2)220–224.

    PubMed  Google Scholar 

  127. Siragusa S, Arcara C, Malato A. et al. 2005; Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol. 16:(Suppl 4)iv136–iv139.

    PubMed  Google Scholar 

  128. Dager WE, King JH, Branch JM. et al. 2005; Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Ann Pharmacother. 39:(7–8)1182–1187.

    PubMed  CAS  Google Scholar 

  129. Kovacs MJ, Anderson D, Morrow B. et al. 2000; Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost. 83:(2)209–211.

    PubMed  CAS  Google Scholar 

  130. Goldhaber SZ, Visani L, De Rosa M. 1999; Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 353:(9162)1386–1389.

    PubMed  CAS  Google Scholar 

  131. Wicki J, Perrier A, Perneger TV. et al. 2000; Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 84:(4)548–552.

    PubMed  CAS  Google Scholar 

  132. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. 2005; Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher. Arch Intern Med. 165:(15)1777–1781.

    PubMed  Google Scholar 

  133. Schoepf UJ, Kucher N, Kipfmueller F. et al. 2004; Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 110:(20)3276–3280.

    PubMed  Google Scholar 

  134. O’Connell CL, Boswell WD, Duddalwar V. et al. 2006; Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 24:(30)4928–4932.

    PubMed  Google Scholar 

  135. Konstantinides S, Geibel A, Heusel G. et al. 2002; Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 347:(15)1143–1150.

    PubMed  CAS  Google Scholar 

  136. Comerota AJ, Aldridge SC. 1993; Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg. 36:(4)359–364.

    PubMed  CAS  Google Scholar 

  137. Mewissen MW, Seabrook GR, Meissner MH. et al. 1999; Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 211:(1)39–49.

    PubMed  CAS  Google Scholar 

  138. Kim HS, Patra A, Paxton BE. et al. 2006; Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. J Vasc Interv Radiol. 17:(7)1099–1104.

    PubMed  Google Scholar 

  139. Hann CL, Streiff MB. 2005; The role of vena caval filters in the management of venous thromboembolism. Blood Rev. 19:(4)179–202.

    PubMed  Google Scholar 

  140. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005; 112:(3)416–422.

    Google Scholar 

  141. Linenberger ML. 2006; Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw. 4:(9)889–901.

    PubMed  Google Scholar 

  142. Streiff MB. 2006; Long-term therapy of venous thromboembolism in cancer patients. J Natl Compr Canc Netw. 4:(9)903–910.

    PubMed  CAS  Google Scholar 

  143. Ansell J, Hirsh J, Poller L. et al. 2004; The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)204S–233S.

    PubMed  CAS  Google Scholar 

  144. Streiff MB, Segal JB, Tamariz LJ. et al. 2006; Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature. Am J Hematol. 81:(9)684–691.

    PubMed  CAS  Google Scholar 

  145. Palareti G, Legnani C, Lee A. et al. 2000; A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 84:(5)805–810.

    PubMed  CAS  Google Scholar 

  146. Prandoni P, Lensing AW, Piccioli A. et al. 2002; Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 100:(10)3484–3488.

    PubMed  CAS  Google Scholar 

  147. Hutten BA, Prins MH, Gent M. et al. 2000; Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 18:(17)3078–3083.

    PubMed  CAS  Google Scholar 

  148. Meyer G, Marjanovic Z, Valcke J. et al. 2002; Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 162:(15)1729–1735.

    PubMed  CAS  Google Scholar 

  149. Deitcher SR, Kessler CM, Merli G. et al. 2006; Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 12:(4)389–396.

    PubMed  CAS  Google Scholar 

  150. Hull RD, Pineo GF, Brant RF,. et al. 2006; Long-term low molecular weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med119:(12)1062–1072.

    PubMed  CAS  Google Scholar 

  151. Lee AY, Levine MN, Baker RI. et al. 2003; Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349:(2)146–153.

    PubMed  CAS  Google Scholar 

  152. Aujesky D, Smith KJ, Cornuz J, Roberts MS. 2005; Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost. 93:(3)592–599.

    PubMed  CAS  Google Scholar 

  153. Bernardi E, Bagatella P, Frulla M. et al. 2001; Postthrombotic syndrome: incidence, prevention, and management. Semin Vasc Med. 1:(1)71–80.

    PubMed  CAS  Google Scholar 

  154. Prandoni P, Villalta S, Bagatella P. et al. 1997; The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 82:(4)423–428.

    PubMed  CAS  Google Scholar 

  155. Prandoni P, Lensing AW, Prins MH. et al. 2004; Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 141:(4)249–256.

    PubMed  Google Scholar 

  156. Brandjes DP, Buller HR, Heijboer H. et al. 1997; Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 349:(9054)759–762.

    PubMed  CAS  Google Scholar 

  157. Crowther MA, Ginsberg JS, Julian J. et al. 2003; A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 349:(12)1133–1138.

    PubMed  CAS  Google Scholar 

  158. Luk C, Wells PS, Anderson D, Kovacs MJ. 2001; Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med. 111:(4)270–273.

    PubMed  CAS  Google Scholar 

  159. Warkentin TE, Greinacher A. 2004; Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)311S–337S.

    PubMed  CAS  Google Scholar 

  160. Sack GH, Jr., Levin J, Bell WR. 1977; Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 56:(1)1–37.

    Google Scholar 

  161. Merli G, Spiro TE, Olsson CG. et al. 2001; Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:(3)191–202.

    PubMed  CAS  Google Scholar 

  162. Zacharski LR, Henderson WG, Rickles FR. et al. 1984; Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 53:(10)2046–2052.

    PubMed  CAS  Google Scholar 

  163. Aisner J, Goutsou M, Maurer LH. et al. 1992; Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. J Clin Oncol. 10:(8)1230–1236.

    PubMed  CAS  Google Scholar 

  164. Maurer LH, Herndon JE, Hollis DR. et al. 1997; Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 15:(11)3378–3387.

    PubMed  CAS  Google Scholar 

  165. Chahinian AP, Propert KJ, Ware JH. et al. 1989; A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 7:(8)993–1002.

    PubMed  CAS  Google Scholar 

  166. Smorenburg SM, Van Noorden CJ. 2001; The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 53:(1)93–105.

    PubMed  CAS  Google Scholar 

  167. Dolovich LR, Ginsberg JS, Douketis JD. et al. 2000; A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 160:(2)181–188.

    PubMed  CAS  Google Scholar 

  168. Kakkar AK, Levine MN, Kadziola Z. et al. 2004; Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 22:(10)1944–1948.

    PubMed  CAS  Google Scholar 

  169. Klerk CP, Smorenburg SM, Otten HM. et al. 2005; The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 23:(10)2130–2135.

    PubMed  CAS  Google Scholar 

  170. Lee AY, Rickles FR, Julian JA. et al. 2005; Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 23:(10)2123–2129.

    PubMed  CAS  Google Scholar 

  171. Altinbas M, Coskun HS, Er O. et al. 2004; A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2:(8)1266–1271.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, 1830 E. Monument Street, Suite 7300, Baltimore, MD, 21205, USA

    Michael B. Streiff

Authors
  1. Michael B. Streiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael B. Streiff .

Editor information

Editors and Affiliations

  1. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

    David S. Ettinger

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science + Business Media, LLC

About this chapter

Cite this chapter

Streiff, M. (2009). Pathogenesis and Management of Venous Thromboembolism in Cancer Patients. In: Ettinger, D.S. (eds) Supportive Care in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-291-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-291-5_6

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-941-3

  • Online ISBN: 978-1-59745-291-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation